

ERLOREN

Erlotinib

Feature	Benefits
Erloren competitively blocks the binding of ATP to its binding site of EGFR	Thereby blocks downstream signaling in tumor cell
Only EGFR inhibitor proven to significantly prolongs survival in relapsed or refractory Non small cell lung cancer as a single agent	Significantly reduces risk of progression & death
Patients receiving Erlotinib had a significantly longer median time to deterioration for all three common lung cancer symptoms	Provides true palliative benefit in not only survival but also symptoms